[Pubmed] An industry update: what's new in the field of therapeutic delivery?

[RSS-Bot]

Ther Deliv. 2022 Mar 7. doi: 10.4155/tde-2022-0011. Online ahead of print.

ABSTRACT

This Industry Update provides an overview of the some of the key events in the pharmaceutical world in December 2021. In this month Eli Lilly & Co invested heavily in drug discovery with deals with Regor Therapeutics on metabolic diseases, and Foghorn Therapeutics on cancer and other diseases caused by faults in the regulation of chromatin unpacking and repacking. Treatments for Covid-19 also feature heavily with the emergency authorization of molnupiravir and Paxlovid™ in the USA, and BiondVax's collaboration agreement with Max Planck and the University Medical Center, Göttingham on their alpaca-based single-chain antibodies targeting the SARS-CoV-2 spike protein. Lastly, this month brought good news on several diseases with poor prognosis and no or limited treatment options. This included Novartis's acquisition of Gyroscope and its gene therapy for age-related macular degeneration, Merck's purchase of Chord Therapeutics and the rights of develop cladribine for generalized myasthenia gravis and neuromyelitis optica spectrum disorders, positive phase III interim results for UCB's, Bimzelx®, in ankylosing spondylitis and AstraZeneca and Ionis co-development and commercialization deal on eplontersen for transthyretin amyloidosis.

PMID:35249356 | DOI:10.4155/tde-2022-0011


Source: https://pubmed.ncbi.nlm.nih.gov/3524935 ... 9&v=2.17.5